Home / Deep Research / Paraneoplastic Neurological Syndromes

Paraneoplastic Neurological Syndromes

Paraneoplastic Neurological Syndromes (PNS): Comprehensive Disease Characteristics Report

2026-05-16
Falcon MONDO:0018215 Model: Edison Scientific Literature 32 citations

Paraneoplastic Neurological Syndromes (PNS): Comprehensive Disease Characteristics Report

1. Disease Information

Overview / definition

Paraneoplastic neurologic(al) syndromes (PNS) are immune-mediated neurologic disorders caused by a remote effect of cancer (i.e., not explained by direct tumor invasion/metastasis, infection, metabolic derangements, or anticancer treatment toxicity) and reflect an antitumor immune response that cross-reacts with neural antigens (graus2021updateddiagnosticcriteria pages 1-2, binks2022paraneoplasticneurologicalsyndromes pages 1-1, vogrig2020epidemiologyofparaneoplastic pages 1-2). The 2021 international consensus update emphasizes the clinical–immunologic–oncologic heterogeneity of PNS and formalizes risk-stratified phenotypes and antibodies for diagnosis (graus2021updateddiagnosticcriteria pages 1-2).

Common synonyms / alternative names

Key identifiers (ontology/coding)

Using the provided toolchain (paper-centric retrieval), explicit MONDO, Orphanet (ORPHA), MeSH descriptor IDs, and specific ICD-10/ICD-11 codes for “paraneoplastic neurological syndromes” were not successfully retrieved from authoritative ontology/coding resources in the current evidence set. Therefore, these identifiers cannot be asserted here without risking fabrication.

Evidence source type note: The present report is derived from aggregated disease-level resources (consensus criteria, population-based cohorts, nationwide testing-performance studies, and real-world observational cohorts), not from individual EHR case records, unless explicitly noted as case series/cohort studies.

Recommended curation action for the knowledge base: supplement this entry with direct pulls from MONDO/Orphanet/MeSH/ICD browsers (outside the current paper-only tool context) to populate stable ontology identifiers.

2. Etiology

Primary causal factors (mechanistic)

PNS are triggered by malignancies that express neuronal (or glial) antigens, generating immune responses that then damage the nervous system. The immune response can be antibody-mediated (particularly for neuronal surface targets) or predominantly T-cell mediated (particularly for intracellular/onconeural antigen targets) (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1).

Risk factors

Cancer types commonly associated: Reviews and population-based data consistently highlight (small-cell) lung cancer, gynecologic tumors (including breast/ovarian associations in some antibody-defined syndromes), thymoma, lymphoma, and neuroblastoma in children as recurring cancer associations (blaes2021pathogenesisdiagnosisand pages 1-3, vogrig2020epidemiologyofparaneoplastic pages 1-2).

Immune checkpoint inhibitor (ICI) exposure as a risk context: The 2021 criteria explicitly provide recommendations for syndromes triggered by ICIs (graus2021updateddiagnosticcriteria pages 1-2). Real-world oncology cohorts show that PNS exacerbations and de novo PNS can occur early during ICI therapy and may lead to ICI interruption and immunosuppressive treatment (nassar2024clinicaloutcomesand pages 3-5, nassar2024clinicaloutcomesand pages 1-2).

Protective factors

No protective genetic variants or environmental protective factors were identified in the current evidence set.

Gene–environment interactions

No established gene–environment interaction evidence was identified in the current evidence set.

3. Phenotypes

Current clinical phenotype framework (2021 PNS-Care)

The updated criteria replace older “classical” terminology with high-risk phenotypes and introduce intermediate-risk phenotypes; antibodies are similarly stratified into high-risk (>70% cancer association), intermediate-risk (30–70%), and lower-risk (<30%) categories (graus2021updateddiagnosticcriteria pages 1-2, graus2021updateddiagnosticcriteria pages 4-6).

Common phenotypes and relative frequencies (population-based)

In a population-based incidence study in Northeastern Italy (2009–2017), the most common definite PNS were limbic encephalitis (31%), cerebellar degeneration (28%), and encephalomyelitis (20%) (vogrig2020epidemiologyofparaneoplastic pages 1-2).

Phenotype characteristics (general)

PNS frequently present with acute/subacute or rapidly progressive neurologic syndromes; in many patients the neurologic syndrome precedes tumor diagnosis, supporting the need for repeated malignancy surveillance when initial screening is negative (blaes2021pathogenesisdiagnosisand pages 1-3).

Quality-of-life / disability impact

PNS are associated with substantial morbidity and mortality at the population level (shah2022populationbasedepidemiologystudy pages 1-3). In a U.S. population-based study (Olmsted County, 1987–2018), total disability-adjusted life years (DALYs) for 28 PNS patients were 472.7 years, indicating large burden from years of life lost plus disability (shah2022populationbasedepidemiologystudy pages 1-3).

Suggested HPO terms (examples; to be curated per patient phenotype)

Because PNS are syndromically diverse, HPO mapping is typically phenotype-specific. Example mappings: - Limbic encephalitis: Seizures (HP:0001250), Memory impairment (HP:0002354), Altered mental status/encephalopathy (e.g., HP:0012638) - Rapidly progressive cerebellar syndrome: Cerebellar ataxia (HP:0001251), Dysarthria (HP:0001260), Nystagmus (HP:0000639) - Sensory neuronopathy: Sensory neuropathy (HP:0000763), Areflexia (HP:0001284)

(These are ontology suggestions; specific term selection should be confirmed against HPO definitions and clinical context.)

4. Genetic / Molecular Information

“Causal genes” and pathogenic variants

PNS are not typically monogenic disorders; no germline causal genes/variants were supported by the current evidence set.

Molecular targets (antigens) implicated by autoantibodies

Instead of inherited gene causality, PNS are commonly defined by immune responses to neural antigens (intracellular or neuronal surface targets). The 2021 criteria and recent reviews list antibody targets including intracellular antigens (e.g., Hu/ANNA1, Yo/PCA1, CV2/CRMP5, Ri/ANNA2, Ma2/Ta, amphiphysin, KLHL11) and surface/extracellular antigens (e.g., NMDAR, LGI1, Caspr2, GABAB receptor, AMPAR, Tr/DNER) (kerstens2024autoimmuneencephalitisand pages 1-2, graus2021updateddiagnosticcriteria pages 4-6).

Suggested gene/protein identifiers (for knowledge base linkage)

Where antibody targets correspond to proteins, they can be linked to HGNC/UniProt entries during curation (e.g., PNMA2 for Ma2/Ta; KLHL11; DNER; AMPH). (Note: this is a linkage suggestion; the current evidence set supports the antibody/antigen names but not specific HGNC IDs.)

5. Environmental Information

No non-cancer environmental toxin/radiation/pollution exposures were supported as causal contributors in the current evidence set.

6. Mechanism / Pathophysiology

Core mechanistic dichotomy

Two broad immunopathogenic categories are emphasized: 1) Intracellular/onconeural antigen–associated PNS: antibodies serve mainly as biomarkers; neuronal injury is thought to be largely T-cell mediated (blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1). 2) Neuronal surface/extracellular antigen–associated PNS: antibodies can be directly pathogenic and these syndromes are often more immunotherapy responsive (blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1).

Causal chain (typical)

Tumor expresses neural antigen → immune priming (humoral and/or cellular) → cross-reactive immune attack on nervous system targets → inflammatory CSF/MRI changes may develop → clinical syndrome consistent with targeted neuroanatomy/receptor physiology (e.g., limbic circuits; cerebellar Purkinje pathways; synaptic receptors) (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, vogrig2020epidemiologyofparaneoplastic pages 1-2).

Immune system involvement (cell types)

Suggested GO biological process terms (examples)

  • Adaptive immune response (GO:0002250)
  • T cell mediated cytotoxicity (GO:0001913)
  • Complement activation (GO:0006956) (more relevant to antibody effector mechanisms; confirm per syndrome)

Suggested Cell Ontology (CL) terms (examples)

(These are ontology suggestions; they should be refined based on syndrome/antibody class.)

7. Anatomical Structures Affected

Organ/system level

Primary involvement is the nervous system (central and/or peripheral). Clinical syndromes include limbic encephalitis, rapidly progressive cerebellar syndrome, encephalomyelitis, sensory neuronopathy, and neuromuscular junction disorders such as LEMS (vogrig2020epidemiologyofparaneoplastic pages 1-2, graus2021updateddiagnosticcriteria pages 4-6).

Suggested UBERON terms (examples)

8. Temporal Development

Onset patterns

The panel proposes that intermediate-risk phenotypes are particularly suggestive when onset is rapidly progressive (<3 months) or accompanied by inflammatory findings in CSF/MRI (graus2021updateddiagnosticcriteria pages 4-6).

Tumor–neurologic timing

PNS can precede tumor diagnosis, motivating structured repeat tumor surveillance strategies when initial screening is negative (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3).

9. Inheritance and Population

Epidemiology (incidence/prevalence)

  • Italy (Friuli-Venezia Giulia, 2009–2017): incidence 0.89/100,000 person-years; prevalence 4.37/100,000; incidence increased over time (0.62 → 0.81 → 1.22 per 100,000 across successive 3-year periods) (vogrig2020epidemiologyofparaneoplastic pages 1-2).
  • United States (Olmsted County, 1987–2018): incidence 0.6/100,000 person-years; prevalence 5.4/100,000; incidence increased from 0.4 to 0.8 per 100,000 person-years comparing 1987–2002 vs 2003–2018 (shah2022populationbasedepidemiologystudy pages 1-3).
  • Consensus estimate in criteria paper: PNS occur in ~1 of 300 cancer patients and population incidence estimates range 1.6–8.9 per million person-years, suggesting underdiagnosis (graus2021updateddiagnosticcriteria pages 1-2).

Morbidity burden statistics

U.S. population-based study estimated 17,099 prevalent cases in the U.S. and predicted DALY burden 292,393 years for all U.S. PNS cases (shah2022populationbasedepidemiologystudy pages 1-3).

10. Diagnostics

Diagnostic criteria (2021 PNS-Care)

The 2021 consensus update defines three evidence levels (definite, probable, possible) using a PNS-Care Score that combines phenotype risk, antibody risk, cancer presence/absence, and follow-up time; except for opsoclonus-myoclonus, definite PNS requires high- or intermediate-risk antibodies (graus2021updateddiagnosticcriteria pages 1-2).

Antibody testing: performance and pitfalls (nationwide real-world data, 2024)

A nationwide Netherlands study (2016–2021) quantified real-world antibody test characteristics and emphasized PPV pitfalls in rare disease testing: - Abstract quote: “Sensitivity and specificity were high (>95%) to very high (>99%) for most tests in both serum and CSF. PPVs for several tests were moderate to poor, especially for serum testing of IA antibodies (25%–80%).” (Neurol Neuroimmunol Neuroinflamm; published 2024-11) (kerstens2024autoimmuneencephalitisand pages 1-2). - Serum CBA-only PPVs for selected surface antibodies were modest and improved with confirmatory tissue-based methods: NMDAR 69.7%, Caspr2 71.7%, GABABR 78.8%, LGI1 91.8%; with IHC confirmation these increased to 97.1%, 94.3%, 100%, 96.4% respectively (kerstens2024autoimmuneencephalitisand pages 2-4). - For a classical onconeural antibody example, anti-Yo PPV improved from 28.8% (immunoblot alone) to 77.8% (immunoblot + IIF) (kerstens2024autoimmuneencephalitisand pages 2-4).

CSF vs serum testing considerations

CSF can be more sensitive for some antibodies (e.g., NMDAR, KLHL11, GFAP, Ri) while for others serum may be more sensitive; importantly, commercial assays can miss CSF antibodies that tissue-based methods detect (e.g., LGI1 and Caspr2 CSF CBA false negatives with positive CSF IHC) (kerstens2024autoimmuneencephalitisand pages 2-4).

CSF/MRI inflammatory support

Population-based PNS definitions often rely on the presence of onconeural antibodies in serum/CSF together with evidence of inflammation such as CSF pleocytosis/OCBs or MRI features suggestive of encephalitis/myelitis (vogrig2020epidemiologyofparaneoplastic pages 1-2).

Imaging/tumor search and real-world implementation

Initial malignancy screening commonly uses whole-body CT and/or FDG-PET/CT with phenotype/antibody-directed targeted testing (e.g., testicular ultrasound; pelvic MRI for suspected teratoma) (vogrig2020epidemiologyofparaneoplastic pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14). If initial screening is negative, repeat tumor screening every 3–6 months initially and then every 6 months up to 4 years has been recommended in recent review guidance (marsili2023paraneoplasticneurologicalsyndromes pages 12-14).

Practical diagnostic workflow

Table (click to expand)
Step Purpose Key actions/tests Evidence/pitfalls Notes on real-world implementation
1. Recognize a compatible syndrome Identify patients who warrant urgent PNS workup Assess for subacute/rapidly progressive neurologic syndromes; classify presentation as high-risk phenotype or possible intermediate-risk phenotype under 2021 PNS-Care framework; exclude direct cancer effects, infection, toxic-metabolic causes, treatment toxicity, stroke, and degenerative disease (graus2021updateddiagnosticcriteria pages 1-2, graus2021updateddiagnosticcriteria pages 4-6, binks2022paraneoplasticneurologicalsyndromes pages 1-1, boldicke2023diagnosisandtreatment pages 4-5) PNS diagnosis is syndromic first, not antibody-first; no neurologic syndrome is exclusively paraneoplastic, so overcalling based on isolated antibody findings is a major pitfall (graus2021updateddiagnosticcriteria pages 1-2, blaes2021pathogenesisdiagnosisand pages 1-3) In practice, neurology-oncology review early in the course improves triage and helps decide whether to pursue full PNS-Care scoring and malignancy search immediately
2. Apply PNS-Care risk logic early Estimate likelihood of true paraneoplastic disease and prioritize workup urgency Combine phenotype risk, antibody risk category, presence/absence of cancer, and follow-up context using PNS-Care approach; note that definite PNS usually requires high- or intermediate-risk antibodies except opsoclonus-myoclonus (graus2021updateddiagnosticcriteria pages 1-2, graus2021updateddiagnosticcriteria media 0aa3f63e) 2021 criteria replace “classical/non-classical” language with high-/intermediate-risk phenotypes and antibodies; probable and definite cases should both be managed urgently (graus2021updateddiagnosticcriteria pages 1-2, dimitrov2026paraneoplasticneurologicalsyndromes pages 1-2) Helpful for standardization, but some real-world patients with likely PNS may still fall below probable/definite thresholds, so clinical judgment remains essential
3. Obtain paired serum and CSF Maximize diagnostic sensitivity and reduce false interpretation Send both serum and CSF for neuronal antibody testing plus routine CSF studies: cell count, protein, oligoclonal bands/IgG index; pair antibody testing with inflammatory markers and syndrome-specific studies (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, vogrig2020epidemiologyofparaneoplastic pages 1-2, boldicke2023diagnosisandtreatment pages 4-5) Serum-only testing can mislead; false positives are suggested by atypical presentations, very low titers, or antibodies found only in serum and not CSF; LGI1 is an exception where serum may be more sensitive (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, kerstens2024autoimmuneencephalitisand pages 2-4) A practical default is “serum + CSF together” at first lumbar puncture to avoid repeat procedures and delayed interpretation
4. Use confirmatory antibody methods, not single commercial assays alone Improve positive predictive value (PPV) and clinical specificity Prefer multistep testing with tissue-based confirmation (IHC/IIF) and/or orthogonal assays instead of relying on isolated immunoblot or CBA results (kerstens2024autoimmuneencephalitisand pages 1-2, kerstens2024autoimmuneencephalitisand pages 2-4) In the Netherlands nationwide study, specificity was usually high, but PPV was only modest for several rare-disease tests; serum CBA-only PPVs were 69.7% for NMDAR, 71.7% for CASPR2, 78.8% for GABABR, and 91.8% for LGI1, improving to 97.1%, 94.3%, 100%, and 96.4% with IHC confirmation; anti-Yo PPV improved from 28.8% with immunoblot alone to 77.8% with immunoblot+IIF (kerstens2024autoimmuneencephalitisand pages 2-4, kerstens2024autoimmuneencephalitisand pages 1-2) Commercial “line blot positive” results should not be acted on in isolation, especially for intracellular/onconeural antibodies in low-pretest-probability settings
5. Interpret antibodies by antigen class and cancer-risk category Link serology to mechanism, prognosis, and tumor search strategy Distinguish intracellular/high-risk antibodies from neuronal-surface antibodies; use high-risk antibodies to direct urgent tumor search and counseling; interpret lower-risk antibodies in syndrome context (graus2021updateddiagnosticcriteria pages 1-2, graus2021updateddiagnosticcriteria pages 4-6, binks2022paraneoplasticneurologicalsyndromes pages 1-1, boldicke2023diagnosisandtreatment pages 4-5) High-risk antibodies have >70% cancer association; intermediate-risk 30%–70%; lower-risk <30%; intracellular antibodies are often markers of T-cell-mediated disease rather than directly pathogenic, whereas surface antibodies are more often directly pathogenic and treatment responsive (graus2021updateddiagnosticcriteria pages 1-2, graus2021updateddiagnosticcriteria pages 4-6, binks2022paraneoplasticneurologicalsyndromes pages 1-1) Reporting should include antigen, sample type, method, titer when available, and risk category—not just “positive/negative”
6. Perform core neurologic phenotyping studies Support syndrome definition and identify inflammatory evidence Obtain MRI brain/spine as indicated, EEG for encephalitic/seizure presentations, EMG/NCS for neuropathy/LEMS, and syndrome-specific testing (marsili2023paraneoplasticneurologicalsyndromes pages 14-15, blaes2021pathogenesisdiagnosisand pages 1-3) CSF pleocytosis, CSF-exclusive oligoclonal bands, and MRI inflammatory changes support autoimmune/paraneoplastic etiologies but are not specific (vogrig2020epidemiologyofparaneoplastic pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14) These studies often provide the “objective inflammation” needed to justify ongoing tumor search even before antibodies return
7. Search for occult malignancy at baseline Detect the causative tumor and satisfy diagnostic criteria Use whole-body CT and/or FDG-PET/CT; add targeted tests guided by phenotype/antibody, such as testicular ultrasound for anti-Ma2/KLHL11 or pelvic imaging for teratoma-associated syndromes (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, vogrig2020epidemiologyofparaneoplastic pages 1-2, blaes2021pathogenesisdiagnosisand pages 1-3) About 80% of patients have positive tumor screening at first assessment in one recent review summary; CT, ultrasound, MRI, and FDG-PET are complementary rather than mutually exclusive (marsili2023paraneoplasticneurologicalsyndromes pages 12-14) Baseline tumor search should be parallel with neurologic workup, not delayed until antibodies finalize
8. Repeat tumor screening when initial studies are negative Capture cancers that are initially occult If first malignancy screen is negative, repeat every 3–6 months initially, then every 6 months for up to 4 years, especially in patients with high-risk phenotypes/antibodies (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3) A common pitfall is stopping after one negative CT; many PNS precede tumor diagnosis, and delayed cancer detection is well recognized (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3) Build repeat imaging into the care plan at discharge so follow-up does not depend on ad hoc reassessment
9. Reassess discordant or low-probability cases Prevent misdiagnosis and unnecessary immunotherapy Revisit alternative diagnoses when syndrome is low-risk, no tumor is found, antibody is low-titer/serum-only, or phenotype-antibody pairing is atypical (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3, kerstens2024autoimmuneencephalitisand pages 1-2) Mass testing in rare diseases lowers PPV; clinically irrelevant positives occur, particularly when ordering broad panels in nonspecific neurologic presentations (kerstens2024autoimmuneencephalitisand pages 1-2, kerstens2024autoimmuneencephalitisand pages 2-4) Multidisciplinary case conference is useful for “positive antibody, wrong phenotype” cases
10. Document diagnostic confidence and act on urgency Translate workup into management pathway Record phenotype, antibody class/risk, cancer status, inflammatory evidence, and final certainty level (possible/probable/definite); begin treatment/tumor-directed management without waiting for perfect certainty when suspicion is strong (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, dimitrov2026paraneoplasticneurologicalsyndromes pages 1-2) The 2021 framework was designed for care and research standardization, but delayed treatment worsens outcomes; probable PNS should not be considered low priority (graus2021updateddiagnosticcriteria pages 1-2, dimitrov2026paraneoplasticneurologicalsyndromes pages 1-2) A practical final note in reports is whether the patient meets or approaches PNS-Care probable/definite thresholds and what further testing would change classification

Table: This table summarizes a practical stepwise diagnostic workflow for suspected paraneoplastic neurological syndromes, integrating the 2021 PNS-Care framework with real-world assay pitfalls and tumor-screening recommendations. It is useful as a concise clinical checklist for applying recent evidence to workup and implementation.

11. Outcome / Prognosis

Population-based outcomes and disability

PNS are rare but can produce high morbidity and mortality. The U.S. population-based cohort quantified a high DALY burden largely driven by years of life lost (shah2022populationbasedepidemiologystudy pages 1-3).

Prognostic associations (observational)

Antibody class and underlying malignancy type are repeatedly highlighted as major determinants of outcome, with intracellular/onconeural syndromes often less responsive to immunotherapy than surface-antibody syndromes (blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1).

12. Treatment

Principles

Treatment is centered on (i) rapid identification and control of the underlying tumor and (ii) prompt immunotherapy when appropriate (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3).

Immunotherapy options (common clinical practice)

First-line immunotherapy approaches commonly include IV corticosteroids, IVIG, and plasma exchange; second-line options commonly include rituximab and cyclophosphamide (marsili2023paraneoplasticneurologicalsyndromes pages 12-14).

ICI-era real-world immunosuppression utilization

In a multicenter real-world cohort of patients with solid tumors and paraneoplastic syndromes treated with ICIs (2015–2022), PNS-directed immunosuppressive therapy was required in 50% (55/109), including steroids (42%), IVIG (12%), rituximab (5%), and plasmapheresis (4%) (nassar2024clinicaloutcomesand pages 3-5).

Suggested MAXO terms (examples)

  • Antineoplastic therapy (MAXO:0000748) (tumor-directed)
  • Glucocorticoid therapy (MAXO term for corticosteroid therapy)
  • Intravenous immunoglobulin therapy (MAXO term)
  • Therapeutic plasma exchange (MAXO term)
  • Anti-CD20 monoclonal antibody therapy (rituximab; MAXO term)

(MAXO IDs should be validated in MAXO; the present evidence supports the interventions but not their MAXO identifiers.)

Clinical trials

No PNS-specific interventional trials were retrieved via the clinical-trials tool in this run; the evidence base in the provided sources is primarily observational and consensus-based (marsili2023paraneoplasticneurologicalsyndromes pages 12-14).

13. Prevention

Primary prevention

There are no established primary prevention strategies for “classic” PNS beyond cancer prevention/early cancer detection in general.

Secondary prevention / early detection

Because PNS can precede the tumor, the main secondary-prevention concept is systematic malignancy search at presentation and scheduled repeat screening when initial workup is negative (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3).

Prevention considerations in the ICI era

Real-world ICI cohorts suggest de novo PNS and PNS exacerbations occur early in the ICI course, supporting careful baseline assessment and early monitoring in high-risk patients (nassar2024clinicaloutcomesand pages 1-2, nassar2024clinicaloutcomesand pages 3-5).

14. Other Species / Natural Disease

No naturally occurring veterinary analogs or cross-species susceptibility data were identified in the current evidence set.

15. Model Organisms

No specific validated animal models of PNS were identified in the current evidence set. Mechanistic inference in the current sources is primarily from human clinical-immunologic observation and translational immunology (binks2022paraneoplasticneurologicalsyndromes pages 1-1, blaes2021pathogenesisdiagnosisand pages 1-3).

Recent developments and “latest research” highlights (prioritizing 2023–2024)

1) Standardization of diagnosis using PNS-Care: the 2021 criteria have become the contemporary diagnostic framework, replacing the 2004 criteria and formalizing risk-stratified phenotypes and antibodies (graus2021updateddiagnosticcriteria pages 1-2).

2) Real-world antibody testing performance and PPV pitfalls (2024 Netherlands nationwide study): despite high specificity, PPV can be modest in rare-disease settings and improves substantially with confirmatory tissue-based testing; this directly affects clinical implementation of broad commercial panels and helps mitigate misdiagnosis (kerstens2024autoimmuneencephalitisand pages 1-2, kerstens2024autoimmuneencephalitisand pages 2-4).

3) ICI-era real-world outcomes and safety (2024 multicenter JITC cohort): patients with paraneoplastic syndromes have been excluded from ICI trials; real-world evidence shows PNS exacerbations occur in 29% of pre-existing PNS patients and can prompt ICI interruption, while overall treatment-related adverse events were similar to matched PNS-free patients in a metastatic NSCLC subgroup (nassar2024clinicaloutcomesand pages 1-2, nassar2024clinicaloutcomesand pages 3-5).

Key statistics (quick reference)

Antibody–phenotype–tumor association summary table

Table (click to expand)
Antibody (common name; target) Antigen location PNS-Care risk category Common neurologic phenotypes Common tumor associations Notes on treatment responsiveness/prognosis
Anti-Hu / ANNA-1 (neuronal nuclear antigens/Hu) Intracellular High risk (>70% cancer association) Limbic encephalitis, encephalomyelitis, sensory neuronopathy; also high-risk CNS/PNS presentations Small-cell lung cancer (SCLC) most typical Intracellular-antigen syndromes are thought to be mainly T-cell mediated; antibodies are diagnostic markers rather than directly pathogenic, and responses to immunotherapy are often limited/variable compared with surface-antibody syndromes (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-Yo / PCA-1 (CDR2/CDR2L) Intracellular High risk Rapidly progressive cerebellar syndrome / paraneoplastic cerebellar degeneration Breast and ovarian/gynecologic cancers Typically associated with cerebellar syndrome; intracellular-antigen profile generally predicts poorer immunotherapy responsiveness and often substantial residual disability (boldicke2023diagnosisandtreatment pages 4-5, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-Ri / ANNA-2 (Nova) Intracellular High risk Opsoclonus-myoclonus-ataxia syndrome, brainstem/cerebellar syndromes Breast cancer; also ovarian cancer and SCLC reported with OMS High-risk onconeural marker; syndrome–tumor pairing helps direct cancer search. As an intracellular-antigen syndrome, prognosis is often driven by rapid recognition and tumor control (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15)
Anti-Ma2 / Ta (PNMA2) Intracellular High risk Limbic encephalitis, diencephalic/brainstem encephalitis, encephalomyelitis, cerebellar syndrome Testicular germ-cell tumors/seminoma most characteristic High cancer association; phenotype often strongly guides tumor search. Like other intracellular-antigen syndromes, pathogenesis is thought to be T-cell dominant and treatment response less robust than with surface-antibody disease (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-CV2 / CRMP5 Intracellular High risk Multifocal CNS/PNS syndromes, neuropathy, encephalitic/brainstem/cerebellar presentations Commonly lung cancer/thymoma in broader PNS literature summarized by reviews High-risk intracellular marker; often part of multifocal PNS presentations. Clinical course can be severe and requires aggressive tumor search plus immunotherapy/tumor treatment (graus2021updateddiagnosticcriteria pages 1-2, blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-amphiphysin (AMPH) Intracellular/synaptic vesicle-associated High risk Stiff-person spectrum disorders; encephalomyelitis/other multifocal syndromes may occur Breast cancer and SCLC are classic associations in review literature Considered a high-risk antibody in the updated framework; some cases may show partial immunotherapy responsiveness, but cancer treatment remains central (graus2021updateddiagnosticcriteria pages 1-2, blaes2021pathogenesisdiagnosisand pages 1-3)
Anti-KLHL11 (Kelch-like protein 11) Intracellular High risk Brainstem encephalitis, cerebellar syndrome, hearing-related rhombencephalitic presentations Testicular seminoma Newly recognized biomarker highlighted in updated reviews; useful for directing tumor screening in men with brainstem/cerebellar syndromes (marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-DNER / Tr (DNER) Surface-associated neuronal protein Intermediate risk (30–70% cancer association) Rapidly progressive cerebellar syndrome Hodgkin lymphoma Representative intermediate-risk antibody; phenotype–tumor pairing is clinically useful. Surface/extracellular-associated antibodies are generally more treatment-responsive than classic intracellular onconeural syndromes, though data remain limited (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-GABA-B receptor (GABABR) Surface receptor Intermediate risk Limbic encephalitis, prominent seizures/intractable epilepsy SCLC commonly associated Surface-antibody disorder with clearer direct antibody pathogenicity and generally better responsiveness to immunotherapy than intracellular-antigen PNS; cancer screening is still essential (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, devine2021paraneoplasticneurologicalsyndromes pages 1-2, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-AMPAR (AMPA receptor) Surface receptor Intermediate risk Limbic encephalitis Thymoma, lung or breast tumors can be associated in review literature Cell-surface antibody syndrome; often more immunotherapy-responsive than high-risk intracellular syndromes, though malignancy search remains mandatory (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-NMDAR (NMDA receptor) Surface receptor Lower risk / not typically classified as high-risk PNS marker Encephalitis/psychiatric and seizure-predominant syndromes Ovarian teratoma; testicular germ-cell tumors also reported May be paraneoplastic or non-paraneoplastic. Surface-antibody mechanism supports direct pathogenicity and typically better response to immunotherapy than intracellular onconeural disorders (boldicke2023diagnosisandtreatment pages 4-5, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-LGI1 (leucine-rich glioma-inactivated 1) Surface/secreted synaptic protein Lower risk Faciobrachial dystonic seizures, autoimmune encephalitis/limbic encephalitis Often no tumor identified Usually not strongly cancer-associated; an important differential when evaluating suspected PNS. Surface-antibody disease is often immunotherapy responsive (boldicke2023diagnosisandtreatment pages 4-5, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-CASPR2 (contactin-associated protein-like 2) Surface/paranodal membrane protein Lower risk Morvan syndrome, encephalitis/peripheral nerve hyperexcitability spectrum Thymoma can occur, but many cases are non-paraneoplastic Lower cancer risk than classic onconeural antibodies; often more responsive to immunotherapy than intracellular-antigen syndromes (boldicke2023diagnosisandtreatment pages 4-5, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)

Table: This table summarizes representative PNS-associated antibodies by antigen location, 2021 PNS-Care risk category, typical neurologic phenotypes, tumor associations, and broad treatment/prognostic implications. It is useful for quickly linking syndrome presentation to antibody interpretation and malignancy search priorities.

URLs and publication dates (where available in evidence)

References

  1. (graus2021updateddiagnosticcriteria pages 1-2): Francesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo, Jean-Christophe G. Antoine, Virginie Desestret, Divyanshu Dubey, Bruno Giometto, Sarosh R. Irani, Bastien Joubert, Frank Leypoldt, Andrew McKeon, Harald Prüss, Dimitri Psimaras, Laure Thomas, Maarten J. Titulaer, Christian A. Vedeler, Jan J. Verschuuren, Josep Dalmau, and Jerome Honnorat. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Jul 2021. URL: https://doi.org/10.1212/nxi.0000000000001014, doi:10.1212/nxi.0000000000001014. This article has 780 citations.

  2. (binks2022paraneoplasticneurologicalsyndromes pages 1-1): Sophie Binks, Christopher Uy, Jerome Honnorat, and Sarosh R Irani. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Practical Neurology, 22:19-31, Sep 2022. URL: https://doi.org/10.1136/practneurol-2021-003073, doi:10.1136/practneurol-2021-003073. This article has 128 citations and is from a peer-reviewed journal.

  3. (vogrig2020epidemiologyofparaneoplastic pages 1-2): Alberto Vogrig, Gian Luigi Gigli, Samantha Segatti, Elisa Corazza, Alessandro Marini, Andrea Bernardini, Francesca Valent, Martina Fabris, Francesco Curcio, Francesco Brigo, Donatella Iacono, Paolo Passadore, Michele Rana, Jérôme Honnorat, and Mariarosaria Valente. Epidemiology of paraneoplastic neurological syndromes: a population-based study. Journal of Neurology, 267:26-35, Sep 2020. URL: https://doi.org/10.1007/s00415-019-09544-1, doi:10.1007/s00415-019-09544-1. This article has 223 citations and is from a domain leading peer-reviewed journal.

  4. (boldicke2023diagnosisandtreatment pages 4-5): T. Böldicke, I. Benhar, D. Chiu, J. Rhee, and L. N. G. Castro. Diagnosis and treatment of paraneoplastic neurologic syndromes. Antibodies, 12:50, Jul 2023. URL: https://doi.org/10.3390/antib12030050, doi:10.3390/antib12030050. This article has 27 citations.

  5. (marsili2023paraneoplasticneurologicalsyndromes pages 12-14): Luca Marsili, Samuel Marcucci, Joseph LaPorta, Martina Chirra, Alberto J. Espay, and Carlo Colosimo. Paraneoplastic neurological syndromes of the central nervous system: pathophysiology, diagnosis, and treatment. Biomedicines, 11:1406, May 2023. URL: https://doi.org/10.3390/biomedicines11051406, doi:10.3390/biomedicines11051406. This article has 53 citations.

  6. (blaes2021pathogenesisdiagnosisand pages 1-3): Franz Blaes. Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes. Expert Review of Neurotherapeutics, 21:675-686, May 2021. URL: https://doi.org/10.1080/14737175.2021.1927713, doi:10.1080/14737175.2021.1927713. This article has 18 citations and is from a peer-reviewed journal.

  7. (nassar2024clinicaloutcomesand pages 3-5): Amin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame, Elias Bou Farhat, Dory Freeman, Edward El-Am, Arjun Ravishankar, Bachar Ahmad, Frank Aboubakar Nana, David Kaldas, Abdul Rafeh Naqash, Elad Sharon, Nicole R LeBoeuf, Alessio Cortellini, Andrea Malgeri, Shruti Gupta, Ahmad Al-Hader, Jeffrey A Sparks, Jenny Linnoila, Ole-Petter R Hamnvik, Tarek H Mouhieddine, Thomas Marron, Kaushal Parikh, Rana R McKay, Thomas Dilling, Toni K Choueiri, Elio Adib, Elie Najem, So Yeon Kim, and Guru Sonpavde. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. Journal for Immunotherapy of Cancer, 12:e008724, Mar 2024. URL: https://doi.org/10.1136/jitc-2023-008724, doi:10.1136/jitc-2023-008724. This article has 8 citations and is from a domain leading peer-reviewed journal.

  8. (nassar2024clinicaloutcomesand pages 1-2): Amin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame, Elias Bou Farhat, Dory Freeman, Edward El-Am, Arjun Ravishankar, Bachar Ahmad, Frank Aboubakar Nana, David Kaldas, Abdul Rafeh Naqash, Elad Sharon, Nicole R LeBoeuf, Alessio Cortellini, Andrea Malgeri, Shruti Gupta, Ahmad Al-Hader, Jeffrey A Sparks, Jenny Linnoila, Ole-Petter R Hamnvik, Tarek H Mouhieddine, Thomas Marron, Kaushal Parikh, Rana R McKay, Thomas Dilling, Toni K Choueiri, Elio Adib, Elie Najem, So Yeon Kim, and Guru Sonpavde. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. Journal for Immunotherapy of Cancer, 12:e008724, Mar 2024. URL: https://doi.org/10.1136/jitc-2023-008724, doi:10.1136/jitc-2023-008724. This article has 8 citations and is from a domain leading peer-reviewed journal.

  9. (graus2021updateddiagnosticcriteria pages 4-6): Francesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo, Jean-Christophe G. Antoine, Virginie Desestret, Divyanshu Dubey, Bruno Giometto, Sarosh R. Irani, Bastien Joubert, Frank Leypoldt, Andrew McKeon, Harald Prüss, Dimitri Psimaras, Laure Thomas, Maarten J. Titulaer, Christian A. Vedeler, Jan J. Verschuuren, Josep Dalmau, and Jerome Honnorat. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Jul 2021. URL: https://doi.org/10.1212/nxi.0000000000001014, doi:10.1212/nxi.0000000000001014. This article has 780 citations.

  10. (shah2022populationbasedepidemiologystudy pages 1-3): Shailee Shah, Eoin P. Flanagan, Pritikanta Paul, Carin Y. Smith, Sandra C. Bryant, Michelle F. Devine, Vanda A. Lennon, Andrew McKeon, Sean J. Pittock, and Divyanshu Dubey. Population-based epidemiology study of paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Mar 2022. URL: https://doi.org/10.1212/nxi.0000000000001124, doi:10.1212/nxi.0000000000001124. This article has 65 citations.

  11. (kerstens2024autoimmuneencephalitisand pages 1-2): Jeroen Kerstens, Marco W.J. Schreurs, Juna M. de Vries, Rinze F. Neuteboom, Juliette Brenner, Yvette S. Crijnen, Robin W. van Steenhoven, Marienke A.A.M. de Bruijn, Agnes van Sonderen, Marleen H. van Coevorden-Hameete, Anna E.M. Bastiaansen, Marie R. Vermeiren, Jan G.M.C. Damoiseaux, Henny G. Otten, Catharina J.M. Frijns, Bob Meek, Anouk C.M. Platteel, Alina van de Mortel, Cathérine C.S. Delnooz, Maarten A.C. Broeren, Marcel M. Verbeek, Erik I. Hoff, Sanae Boukhrissi, Suzanne C. Franken, Mariska M.P. Nagtzaam, Manuela Paunovic, Sharon Veenbergen, Peter A.E. Sillevis Smitt, and Maarten J. Titulaer. Autoimmune encephalitis and paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Nov 2024. URL: https://doi.org/10.1212/nxi.0000000000200318, doi:10.1212/nxi.0000000000200318. This article has 32 citations.

  12. (kerstens2024autoimmuneencephalitisand pages 2-4): Jeroen Kerstens, Marco W.J. Schreurs, Juna M. de Vries, Rinze F. Neuteboom, Juliette Brenner, Yvette S. Crijnen, Robin W. van Steenhoven, Marienke A.A.M. de Bruijn, Agnes van Sonderen, Marleen H. van Coevorden-Hameete, Anna E.M. Bastiaansen, Marie R. Vermeiren, Jan G.M.C. Damoiseaux, Henny G. Otten, Catharina J.M. Frijns, Bob Meek, Anouk C.M. Platteel, Alina van de Mortel, Cathérine C.S. Delnooz, Maarten A.C. Broeren, Marcel M. Verbeek, Erik I. Hoff, Sanae Boukhrissi, Suzanne C. Franken, Mariska M.P. Nagtzaam, Manuela Paunovic, Sharon Veenbergen, Peter A.E. Sillevis Smitt, and Maarten J. Titulaer. Autoimmune encephalitis and paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Nov 2024. URL: https://doi.org/10.1212/nxi.0000000000200318, doi:10.1212/nxi.0000000000200318. This article has 32 citations.

  13. (graus2021updateddiagnosticcriteria media 0aa3f63e): Francesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo, Jean-Christophe G. Antoine, Virginie Desestret, Divyanshu Dubey, Bruno Giometto, Sarosh R. Irani, Bastien Joubert, Frank Leypoldt, Andrew McKeon, Harald Prüss, Dimitri Psimaras, Laure Thomas, Maarten J. Titulaer, Christian A. Vedeler, Jan J. Verschuuren, Josep Dalmau, and Jerome Honnorat. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Jul 2021. URL: https://doi.org/10.1212/nxi.0000000000001014, doi:10.1212/nxi.0000000000001014. This article has 780 citations.

  14. (dimitrov2026paraneoplasticneurologicalsyndromes pages 1-2): Stoimen Dimitrov, Mihael Tsalta-Mladenov, Plamena Kabakchieva, Tsvetoslav Georgiev, and Silva Andonova. Paraneoplastic neurological syndromes: advances and future perspectives in immunopathogenesis and management. Antibodies, 15:8, Jan 2026. URL: https://doi.org/10.3390/antib15010008, doi:10.3390/antib15010008. This article has 2 citations.

  15. (marsili2023paraneoplasticneurologicalsyndromes pages 14-15): Luca Marsili, Samuel Marcucci, Joseph LaPorta, Martina Chirra, Alberto J. Espay, and Carlo Colosimo. Paraneoplastic neurological syndromes of the central nervous system: pathophysiology, diagnosis, and treatment. Biomedicines, 11:1406, May 2023. URL: https://doi.org/10.3390/biomedicines11051406, doi:10.3390/biomedicines11051406. This article has 53 citations.

  16. (devine2021paraneoplasticneurologicalsyndromes pages 1-2): Michelle F. Devine, Naga Kothapalli, Mahmoud Elkhooly, and Divyanshu Dubey. Paraneoplastic neurological syndromes: clinical presentations and management. Therapeutic Advances in Neurological Disorders, Jan 2021. URL: https://doi.org/10.1177/1756286420985323, doi:10.1177/1756286420985323. This article has 102 citations and is from a peer-reviewed journal.

Artifacts